Article

Collaboration: Pfizer, Eyetech in deal for AMD, DME therapy

New York-Pfizer Inc. and Eyetech Pharmaceuticals Inc. will jointly develop and commercialize Eyetech's pegaptanib sodium (Macugen) as a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Related Content
Small hyperreflective retinal foci: An in vivo imaging feature of resident microglia activation in geographic atrophy
October 5th 2024

Small hyperreflective retinal foci: An in vivo imaging feature of resident microglia activation in geographic atrophy

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

Wilmer Eye Institute receives $10 million donation from James and Heather Gills
October 3rd 2024

Wilmer Eye Institute receives $10 million donation from James and Heather Gills

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

Harrow relaunches triamcinolone acetonide injectable suspension
October 3rd 2024

Harrow relaunches triamcinolone acetonide injectable suspension

NYU Langone receives $1.6 million grant from NIH to study Alzheimer, Parkinson progression
October 3rd 2024

NYU Langone receives $1.6 million grant from NIH to study Alzheimer, Parkinson progression

© 2024 MJH Life Sciences

All rights reserved.